| abstract |
New pharmaceutically active compounds of formula (I), wherein: a is oxygen, CH2, C (CH3) 2, NR10, sulfur, SO or SO2; b is oxygen, CH2, C = O, C = NR11, C = NOH, SO2, sulfur, SO, C = NO-C1-5 alkyl or CR7R8; R1 to R8 are each independently selected from hydrogen, halo (for example, chlorine, fluoro, bromine or iodine), trifluoromethyl, cyano and hydroxy, or R7 and R8 together may be C (= O) NH2 or C (= O) N-C1-4alkyl, with the proviso that neither R7 nor R8 can be halo when not, NR11, sulfur, SO or SO2; and each of R10 and R11 are independently selected from hydrogen, benzyl and C1-6alkyl; and pharmaceutically acceptable salts of said compounds. These compounds have central dopaminergic activity and are useful in the treatment of disorders of the central nervous system. |